Total | Men | Women | ||||
HR (95% CI) | P value | HR (95% CI) | P value | HR (95% CI) | P value | |
All-cause death* (type 1 MI, ref cat) | ||||||
Model 1 (crude) | 2.32 (2.20 to 2.44) | <0.001 | 3.06 (2.85 to 3.28) | <0.001 | 1.77 (1.64 to 1.91) | <0.001 |
Model 2 (model 1+adjusted for comorbidities) | 1.44 (1.36 to 1.51) | <0.001 | 1.54 (1.43 to 1.65) | <0.001 | 1.32 (1.23 to 1.43) | <0.001 |
Model 3 (model 2+adjusted for hs-cTnT concentrations) | 1.45 (1.38 to 1.53) | <0.001 | 1.55 (1.44 to 1.67) | <0.001 | 1.34 (1.24 to 1.45) | <0.001 |
Major adverse cardiovascular events† (type 1 MI, ref cat) | ||||||
Model 1 (crude) | 2.00 (1.91 to 2.10) | <0.001 | 2.49 (2.34 to 2.66) | <0.001 | 1.62 (1.51 to 1.73) | <0.001 |
Model 2 (model 1+adjusted for comorbidities) | 1.30 (1.24 to 1.36) | <0.001 | 1.34 (1.25 to 1.43) | <0.001 | 1.24 (1.16 to 1.33) | <0.001 |
Model 3 (model 2+adjusted for hs-cTnT concentrations) | 1.31 (1.25 to 1.37) | <0.001 | 1.35 (1.26 to 1.44) | <0.001 | 1.25 (1.17 to 1.35) | <0.001 |
Model 1: MI type, sex, hospital site, year; model 2: model 1+age, current smoking, hypertension, diabetes, hyperlipidaemia, coronary artery disease, congestive heart failure, previous stroke, ST-segment depression, estimated glomerular filtration rate, COPD, dementia, previous or present cancer; model 3: model 2+hs-cTnT levels. In sex-stratified analysis, sex is not included in the models.
*Total, n=47 760; women, n=16 664; men, n=31 096. Pinteraction MI status×sex=0.009.
†Total, n=45 863; women, n=16 038; men, n=29 825. Pinteraction MI status×sex=0.152.
COPD, chronic obstructive pulmonary disease; hs-cTnT, high-sensitivity cardiac troponin T; MI, myocardial infarction; ref cat, reference category.